The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Morie GertzThe Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Morie Gertz, Mayo Clinic, Rochester, US, answers the question: Is patient quality of life superior with CAR T or stem cell transplant?
Morie Gertz discusses patient quality of life issues comparing CAR T treatment versus stem cell transplant. He describes the associated toxicities of both treatment modalities and explains that treatment is guided by the patient's disease stage e.g. stem cell transplantation is offered early in the treatment pathway, whilst CAR T therapy is mainly offered to patients with very advanced disease. He concludes by describing an upcoming trial that will compare both these treatments as maintenance, where the clear distinction between treatment superiority on quality of life can be made.
Is patient quality of life superior with CAR T or stem cell transplant?